Login now to access Regular content available to all registered users.
Abstract
Discussion Forum (0)
Introduction: Immunization during pregnancy has been historically low, with a Tdap administration rate during pregnancy of 54.4%. During the COVID-19 pandemic, there has been a decrease in pediatric vaccination administration. During the height of the COVID pandemic in New Jersey, mid-March through mid-May, the state had the second highest rate of positive cases in the US. To assess changes to maternal and neonatal vaccinations rates during the COVID-19 pandemic, the following retrospective cohort study was performed.
Methods: All patients who delivered at an urban institution from March 21 to May 31 in 2019 and 2020 were identified, and the vaccination rates were compared. The pandemic response included an option for telehealth visits, with weekly in-person visits from 36-40 weeks. HPV vaccination was recommended in the immediate postpartum period for eligible patients, in addition to Tdap, MMR, Varicella and neonatal hepatitis B vaccination as indicated.
Results: Maternal characteristics and obstetrical outcomes were similar between the two groups. There was no difference in number of prenatal visits. There was an increase in third trimester Tdap vaccination administration in the 2020 cohort, 37% vs. 60% (p < 0.0001). When combined with Tdap administration in the immediate postpartum period, Tdap administration increased to 79.5% in 2019 and 82.4% in 2020 (p=0.46). There were no differences in maternal or neonatal vaccination administration in the immediate postpartum period.
Conclusion/Implications: Maternal and neonatal vaccine administration in the immediate postpartum period was maintained despite the COVID-19 pandemic. The high rates of vaccine administration could inform providers as the influenza season begins.
Methods: All patients who delivered at an urban institution from March 21 to May 31 in 2019 and 2020 were identified, and the vaccination rates were compared. The pandemic response included an option for telehealth visits, with weekly in-person visits from 36-40 weeks. HPV vaccination was recommended in the immediate postpartum period for eligible patients, in addition to Tdap, MMR, Varicella and neonatal hepatitis B vaccination as indicated.
Results: Maternal characteristics and obstetrical outcomes were similar between the two groups. There was no difference in number of prenatal visits. There was an increase in third trimester Tdap vaccination administration in the 2020 cohort, 37% vs. 60% (p < 0.0001). When combined with Tdap administration in the immediate postpartum period, Tdap administration increased to 79.5% in 2019 and 82.4% in 2020 (p=0.46). There were no differences in maternal or neonatal vaccination administration in the immediate postpartum period.
Conclusion/Implications: Maternal and neonatal vaccine administration in the immediate postpartum period was maintained despite the COVID-19 pandemic. The high rates of vaccine administration could inform providers as the influenza season begins.
Introduction: Immunization during pregnancy has been historically low, with a Tdap administration rate during pregnancy of 54.4%. During the COVID-19 pandemic, there has been a decrease in pediatric vaccination administration. During the height of the COVID pandemic in New Jersey, mid-March through mid-May, the state had the second highest rate of positive cases in the US. To assess changes to maternal and neonatal vaccinations rates during the COVID-19 pandemic, the following retrospective cohort study was performed.
Methods: All patients who delivered at an urban institution from March 21 to May 31 in 2019 and 2020 were identified, and the vaccination rates were compared. The pandemic response included an option for telehealth visits, with weekly in-person visits from 36-40 weeks. HPV vaccination was recommended in the immediate postpartum period for eligible patients, in addition to Tdap, MMR, Varicella and neonatal hepatitis B vaccination as indicated.
Results: Maternal characteristics and obstetrical outcomes were similar between the two groups. There was no difference in number of prenatal visits. There was an increase in third trimester Tdap vaccination administration in the 2020 cohort, 37% vs. 60% (p < 0.0001). When combined with Tdap administration in the immediate postpartum period, Tdap administration increased to 79.5% in 2019 and 82.4% in 2020 (p=0.46). There were no differences in maternal or neonatal vaccination administration in the immediate postpartum period.
Conclusion/Implications: Maternal and neonatal vaccine administration in the immediate postpartum period was maintained despite the COVID-19 pandemic. The high rates of vaccine administration could inform providers as the influenza season begins.
Methods: All patients who delivered at an urban institution from March 21 to May 31 in 2019 and 2020 were identified, and the vaccination rates were compared. The pandemic response included an option for telehealth visits, with weekly in-person visits from 36-40 weeks. HPV vaccination was recommended in the immediate postpartum period for eligible patients, in addition to Tdap, MMR, Varicella and neonatal hepatitis B vaccination as indicated.
Results: Maternal characteristics and obstetrical outcomes were similar between the two groups. There was no difference in number of prenatal visits. There was an increase in third trimester Tdap vaccination administration in the 2020 cohort, 37% vs. 60% (p < 0.0001). When combined with Tdap administration in the immediate postpartum period, Tdap administration increased to 79.5% in 2019 and 82.4% in 2020 (p=0.46). There were no differences in maternal or neonatal vaccination administration in the immediate postpartum period.
Conclusion/Implications: Maternal and neonatal vaccine administration in the immediate postpartum period was maintained despite the COVID-19 pandemic. The high rates of vaccine administration could inform providers as the influenza season begins.
Did the COVID pandemic affect vaccination rates in the immediate postpartum period?
Kaila Krishnamoorthy
Abstract
Discussion Forum (0)
Introduction: Immunization during pregnancy has been historically low, with a Tdap administration rate during pregnancy of 54.4%. During the COVID-19 pandemic, there has been a decrease in pediatric vaccination administration. During the height of the COVID pandemic in New Jersey, mid-March through mid-May, the state had the second highest rate of positive cases in the US. To assess changes to maternal and neonatal vaccinations rates during the COVID-19 pandemic, the following retrospective cohort study was performed.
Methods: All patients who delivered at an urban institution from March 21 to May 31 in 2019 and 2020 were identified, and the vaccination rates were compared. The pandemic response included an option for telehealth visits, with weekly in-person visits from 36-40 weeks. HPV vaccination was recommended in the immediate postpartum period for eligible patients, in addition to Tdap, MMR, Varicella and neonatal hepatitis B vaccination as indicated.
Results: Maternal characteristics and obstetrical outcomes were similar between the two groups. There was no difference in number of prenatal visits. There was an increase in third trimester Tdap vaccination administration in the 2020 cohort, 37% vs. 60% (p < 0.0001). When combined with Tdap administration in the immediate postpartum period, Tdap administration increased to 79.5% in 2019 and 82.4% in 2020 (p=0.46). There were no differences in maternal or neonatal vaccination administration in the immediate postpartum period.
Conclusion/Implications: Maternal and neonatal vaccine administration in the immediate postpartum period was maintained despite the COVID-19 pandemic. The high rates of vaccine administration could inform providers as the influenza season begins.
Methods: All patients who delivered at an urban institution from March 21 to May 31 in 2019 and 2020 were identified, and the vaccination rates were compared. The pandemic response included an option for telehealth visits, with weekly in-person visits from 36-40 weeks. HPV vaccination was recommended in the immediate postpartum period for eligible patients, in addition to Tdap, MMR, Varicella and neonatal hepatitis B vaccination as indicated.
Results: Maternal characteristics and obstetrical outcomes were similar between the two groups. There was no difference in number of prenatal visits. There was an increase in third trimester Tdap vaccination administration in the 2020 cohort, 37% vs. 60% (p < 0.0001). When combined with Tdap administration in the immediate postpartum period, Tdap administration increased to 79.5% in 2019 and 82.4% in 2020 (p=0.46). There were no differences in maternal or neonatal vaccination administration in the immediate postpartum period.
Conclusion/Implications: Maternal and neonatal vaccine administration in the immediate postpartum period was maintained despite the COVID-19 pandemic. The high rates of vaccine administration could inform providers as the influenza season begins.
Introduction: Immunization during pregnancy has been historically low, with a Tdap administration rate during pregnancy of 54.4%. During the COVID-19 pandemic, there has been a decrease in pediatric vaccination administration. During the height of the COVID pandemic in New Jersey, mid-March through mid-May, the state had the second highest rate of positive cases in the US. To assess changes to maternal and neonatal vaccinations rates during the COVID-19 pandemic, the following retrospective cohort study was performed.
Methods: All patients who delivered at an urban institution from March 21 to May 31 in 2019 and 2020 were identified, and the vaccination rates were compared. The pandemic response included an option for telehealth visits, with weekly in-person visits from 36-40 weeks. HPV vaccination was recommended in the immediate postpartum period for eligible patients, in addition to Tdap, MMR, Varicella and neonatal hepatitis B vaccination as indicated.
Results: Maternal characteristics and obstetrical outcomes were similar between the two groups. There was no difference in number of prenatal visits. There was an increase in third trimester Tdap vaccination administration in the 2020 cohort, 37% vs. 60% (p < 0.0001). When combined with Tdap administration in the immediate postpartum period, Tdap administration increased to 79.5% in 2019 and 82.4% in 2020 (p=0.46). There were no differences in maternal or neonatal vaccination administration in the immediate postpartum period.
Conclusion/Implications: Maternal and neonatal vaccine administration in the immediate postpartum period was maintained despite the COVID-19 pandemic. The high rates of vaccine administration could inform providers as the influenza season begins.
Methods: All patients who delivered at an urban institution from March 21 to May 31 in 2019 and 2020 were identified, and the vaccination rates were compared. The pandemic response included an option for telehealth visits, with weekly in-person visits from 36-40 weeks. HPV vaccination was recommended in the immediate postpartum period for eligible patients, in addition to Tdap, MMR, Varicella and neonatal hepatitis B vaccination as indicated.
Results: Maternal characteristics and obstetrical outcomes were similar between the two groups. There was no difference in number of prenatal visits. There was an increase in third trimester Tdap vaccination administration in the 2020 cohort, 37% vs. 60% (p < 0.0001). When combined with Tdap administration in the immediate postpartum period, Tdap administration increased to 79.5% in 2019 and 82.4% in 2020 (p=0.46). There were no differences in maternal or neonatal vaccination administration in the immediate postpartum period.
Conclusion/Implications: Maternal and neonatal vaccine administration in the immediate postpartum period was maintained despite the COVID-19 pandemic. The high rates of vaccine administration could inform providers as the influenza season begins.
{{ help_message }}
{{filter}}